Literature DB >> 19880327

Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFalpha and IL-1beta.

Jaewoo Hong1, Suyoung Bae, Youngsun Kang, Doyoung Yoon, Xiyuan Bai, Edward D Chan, Tania Azam, Charles A Dinarello, Siyoung Lee, Erk Her, Gyujin Rho, Soohyun Kim.   

Abstract

Targeting major proinflammatory cytokines such as IL-1beta and TNFalpha is of great interest in patients with chronic inflammatory diseases, including rheumatoid arthritis, colitis, and psoriasis. The cytokine Interleukin (IL)-32 induces proinflammatory cytokines such as TNFalpha, IL-1beta, IL-6, and chemokines. We previously used an IL-32 ligand-affinity column to purify proteinase 3, which is abundantly expressed in neutrophil and monocytic leukocytes but not in other cell types, and found that IL-32 is mainly produced by monocytic leukocytes. This evidence suggested that silencing endogenous IL-32 by short hairpin RNA (shRNA) in monocytic cells might reveal the precise function of endogenous IL-32. Indeed, lipopolysaccharide (LPS)- or phorbol myristate acetate (PMA)-induced proinflammatory cytokine production was significantly inhibited in shRNA/IL-32 stable clones as compared to control clones. Furthermore, macrophages in PMA-differentiated shRNA/IL-32 stable clones displayed remarkably impaired LPS- and IL-1beta-induced proinflammatory cytokine production. These data suggest that IL-32 is not only involved in host defense against pathogens, but also might play a role in chronic inflammatory diseases. IL-32 production leads to major proinflammatory cytokine production during the initial immune response. Copyright 2009. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19880327     DOI: 10.1016/j.cyto.2009.10.003

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  29 in total

1.  Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis.

Authors:  Jida Choi; Suyoung Bae; Jaewoo Hong; Soyoon Ryoo; Hyunjhung Jhun; Kwangwon Hong; Doyoung Yoon; Siyoung Lee; Erk Her; Wonhyuk Choi; Jeonghwan Kim; Tania Azam; Charles A Dinarello; Soohyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

2.  Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.

Authors:  Kun-Yi Lai; Ya-Ching Chou; Jiun-Han Lin; Yi Liu; Kai-Min Lin; Shin-Lian Doong; Mei-Ru Chen; Te-Huei Yeh; Sue-Jane Lin; Ching-Hwa Tsai
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

3.  IL-32 expression in the airway epithelial cells of patients with Mycobacterium avium complex lung disease.

Authors:  Xiyuan Bai; Alida R Ovrutsky; Marinka Kartalija; Kathryn Chmura; Amanda Kamali; Jennifer R Honda; Rebecca E Oberley-Deegan; Charles A Dinarello; James D Crapo; Ling-Yi Chang; Edward D Chan
Journal:  Int Immunol       Date:  2011-10-27       Impact factor: 4.823

4.  Knockdown of IL-32 protects PC12 cells against oxygen-glucose deprivation/reoxygenation-induced injury via activation of Nrf2/NF-κB pathway.

Authors:  Hua Yin; Meiyu Wu; Yue Jia
Journal:  Metab Brain Dis       Date:  2020-01-08       Impact factor: 3.584

5.  Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model.

Authors:  A Mario Marcondes; Xiang Li; Laura Tabellini; Matthias Bartenstein; Julia Kabacka; George E Sale; John A Hansen; Charles A Dinarello; H Joachim Deeg
Journal:  Blood       Date:  2011-09-06       Impact factor: 22.113

Review 6.  Role of interleukin-32 in chronic rhinosinusitis.

Authors:  Anjeni Keswani; Robert C Kern; Robert P Schleimer; Atsushi Kato
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-02

7.  IL-32 expression is an independent prognostic marker for gastric cancer.

Authors:  Sumiya Ishigami; Takaaki Arigami; Yasuto Uchikado; Tetsuro Setoyama; Yoshiaki Kita; Ken Sasaki; Hiroshi Okumura; Hiroshi Kurahara; Yuko Kijima; Aya Harada; Shinichi Ueno; Shoji Natsugoe
Journal:  Med Oncol       Date:  2013-03-12       Impact factor: 3.064

8.  Preliminary characterization of IL32 in basal-like/triple negative compared to other types of breast cell lines and tissues.

Authors:  Audrey Player; Tim Oguamanam; Jennifer Okanmelu; Kayla Burrell; Mario Hollomon
Journal:  BMC Res Notes       Date:  2014-08-07

9.  Human Interleukin-32γ Plays a Protective Role in an Experimental Model of Visceral Leishmaniasis in Mice.

Authors:  Leo A B Joosten; Fátima Ribeiro-Dias; Rodrigo Saar Gomes; Muriel Vilela Teodoro Silva; Jéssica Cristina Dos Santos; Christine van Linge; Juliana Machado Reis; Mauro Martins Teixeira; Sebastião Alves Pinto; Miriam Leandro Dorta; Xiyuan Bai; Edward D Chan; Charles A Dinarello; Milton Adriano Pelli Oliveira
Journal:  Infect Immun       Date:  2018-04-23       Impact factor: 3.441

Review 10.  Novel insights into the biology of interleukin-32.

Authors:  Leo A B Joosten; Bas Heinhuis; Mihai G Netea; Charles A Dinarello
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.